GB Sciences Inc (GBLX) Kazanmak

GB Sciences, Inc. is a biopharmaceutical research and development company, which engages in creating patented, disease-targeted formulations of cannabis, and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The company is headquartered in Las Vegas, Nevada and currently employs 2 full-time employees. The company went IPO on 2003-12-22. The company creates patented, disease-targeted formulations of cannabis and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. (GBSGB). The primary focus for the development of its lead program has been in evaluating suitable development partners that will assist it in preparing its cannabinoid-based formulas for the treatment of the motor symptoms of Parkinson's disease in human clinical trials. The company is engaged in the research and development of plant-inspired medicines, with virtual operations in North America and Europe. GBSGB’s has a portfolio of intellectual property containing both proprietary plant-inspired formulations and its artificial intelligence-enabled drug discovery platform, and critical research contracts and key supplier arrangements. Its intellectual property covers a range of 65 medical conditions.